Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BioAtla, Inc.

Get SEC filing alerts via email and in your feed for BioAtla, Inc.

BCAB

BioAtla, Inc.

About BioAtla, Inc.

BioAtla, Inc. is a clinical-stage biopharmaceutical company specializing in conditionally active biologics (CABs), a novel class of antibody-based therapeutics targeting solid tumor cancers. Its proprietary CAB technology exploits tumor microenvironment acidity to selectively bind cancer cells, reducing off-tumor toxicity. BioAtla develops monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and CAR-T therapies, focusing on improving cancer treatment efficacy and safety through enhanced tumor specificity.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BioAtla, Inc.

1
1
BioAtla, Inc. BioAtla Reports $6.3 Million Net Loss in Q1 2026, Announces Strategic Review

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
BioAtla, Inc. BioAtla Reports $59.6 Million Net Loss and Revenue Decline to $2.0 Million for 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
BioAtla, Inc. BioAtla Reports Zero Revenue and Increased Losses in Latest Financial Filing

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BioAtla, Inc. BioAtla Reports $18.7 Million Net Loss in Q2 2025, Sees Decrease in Operating Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BioAtla, Inc. BioAtla Reports $15.3 Million Net Loss in Q1 2025, Implements Workforce Reduction

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
BioAtla, Inc. BioAtla Reports $69.7 Million Net Loss for Fiscal Year 2024, Highlights Strategic Improvements

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
BioAtla, Inc. BioAtla, Inc. Reports Significant Financial Changes, Net Loss Decrease in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments